Remdesivir, a drug developed through a federal grant to UAB, may be the first effective therapy for treating severely ill COVID-19 patients, early analysis of a large federally sponsored study found this week. The drug reduced hospital stays by one-third and produced fewer adverse side effects, according to two UAB doctors who participated in the international trial. Read more.